Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ION-682884 (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)
2024-514434-20-00Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Sep 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing Eplontersen arm with Placebo arm (2 arms). Primary endpoint: Composite of cardiovascular death and recurrent cardiovascular clinical events. Started Sep 2024; status: completed.
02
Drugs
eplontersen
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2024-514434-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514434-20-00.